Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This adult-focused literature review proposes a fiber–microbiota–intestinal-barrier framework linking leukemia treatment-associated ecosystem disruption to reduced microbial metabolites, barrier dysfunction, infection risk, immune dysregulation, toxicity, and altered drug exposure, while calling for integrated prospective trials.
The reviewed literature supports associations among leukemia care, microbiome disruption, loss of fermentative function, and adverse host effects; the unproven therapeutic inference is that carefully timed and safety-bounded microbiota-directed nutrition could restore this axis and improve treatment outcomes.
In a retrospective single-center cohort of 40 pediatric patients with high-risk AML undergoing myeloablative allogeneic HCT in MRD-negative first remission, receiving 3–4 rather than 1–2 pre-transplant chemotherapy cycles was not associated with statistically significant differences in survival or relapse outcomes.
The observed lack of significant outcome improvement with 3–4 cycles supports the hypothesis—not established by this underpowered observational study—that proceeding to HCT after 1–2 cycles once MRD-negative CR1 is achieved could avoid unnecessary chemotherapy exposure without compromising transplant outcomes.
In a prospective pediatric CNS tumor cohort, CSF collected at dural opening or through ventricular catheters produced comparable cfDNA yields, yield varied by tumor location and grade, and a predictive model estimated that 3.35 ml of CSF would permit NGS processing in 90% of samples.
The study provides evidence that standardized CSF acquisition may improve the feasibility of tumor genomic profiling; it is reasonable but unproven to infer that more reliable profiling could eventually support diagnosis or molecular treatment selection, because clinical actionability and patient outcomes were not evaluated.
A 138-person single-centre RASopathy cohort integrated with a systematic literature review found syndrome- and genotype-associated differences in solid-tumour burden, including frequent bladder tumours in Costello syndrome and predominantly low-grade CNS tumours in Noonan syndrome.
The evidence supports risk stratification rather than treatment: if the reported syndrome- and variant-specific associations are validated prospectively, they could inform tailored tumour surveillance and earlier detection; any resulting improvement in clinical outcomes remains inferential.
In a FAERS analysis of 492 reported pediatric tisagenlecleucel-treated r/r B-ALL cases, 149 included infection-related events that clustered early, were associated with higher reported mortality, and generated disproportionate-reporting signals for Clostridioides difficile, influenza virus, and adenovirus.
The record supports hypothesis generation—not clinical validation—that intensified early infection surveillance, longer-term vigilance, and attention to selected pathogens, hypogammaglobulinemia, and hypoxia might help identify high-risk pediatric tisagenlecleucel recipients; whether targeted monitoring or prophylaxis improves outcomes requires prospective testing.
In a 30-participant randomized trial, a supervised in-hospital aerobic, resistance, and breathing exercise program was deliverable without recorded intervention-related adverse events requiring permanent discontinuation but was not superior to minimal active physiotherapy for fatigue, quality of life, strength, or functional capacity.
The trial provides evidence of supervised protocol feasibility but not efficacy over breathing exercises plus ambulation guidance; as an inference requiring larger, better-controlled studies, structured exercise may still help preserve function in selected hospitalized pediatric oncology patients if intervention exposure, fidelity, timing, and patient stratification are optimized.
In 260 undernourished children with cancer, low circulating micronutrient concentrations were common and associated with selected adverse outcomes, while six weeks of RUTF plus standard nutritional therapy produced limited and inconsistent micronutrient improvements compared with standard therapy alone.
The study provides evidence that RUTF may modestly improve selected zinc and vitamin B12 measures, but not micronutrient status consistently; it is an inference—not established by this record—that targeted, deficiency-guided supplementation could reduce treatment delays, toxicity, or mortality, and this requires dedicated interventional trials.
This multi-database landscape analysis reports that hepatoblastoma research and trials are dominated by cisplatin and a narrow set of targets, with scarce late-phase trials, geographic inequality, and comparatively limited study of Hippo/YAP and immune-checkpoint biology.
The record supports prioritizing diversification of hepatoblastoma therapeutic research beyond cisplatin and currently concentrated targets; it is an inference—not demonstrated treatment efficacy—that investigating Hippo/YAP, immune checkpoints, multi-omics-guided targets, or pediatric-specific models could reveal strategies for resistant disease.
In a retrospective cohort of 1,070 patients aged 2–20 years with newly diagnosed ALL, higher diagnostic BMI was associated with transaminitis and conjugated hyperbilirubinemia, while induction-phase weight loss was associated with greater post-induction conjugated hyperbilirubinemia risk.
The reported associations support evaluating diagnostic BMI and induction weight loss as readily available hepatotoxicity risk markers; it remains an untested inference that nutrition-directed management, altered monitoring, or other hepatoprotective interventions based on these markers would reduce toxicity or improve treatment outcomes.
This narrative review describes pediatric papillary thyroid carcinoma as clinically and biologically distinct from adult disease, emphasizing fusion drivers such as RET/PTC, NTRK, and ALK, generally favorable survival despite advanced presentation, and the emerging use of RET and NTRK inhibitors for refractory or metastatic disease.
The supplied review indicates that actionable RET or NTRK fusions occur as important drivers in pediatric PTC and that corresponding inhibitors are being used in refractory or metastatic disease; it is reasonable—but not established by primary data in this record—to hypothesize that fusion-guided treatment selection could improve disease control while supporting more tailored management.
In a retrospective cohort of 209 pathologically confirmed HCC cases, a super-resolution CEMRI radiomics model combining intratumoral and 5-mm peritumoral features predicted MTM-HCC in a held-out test set (AUC 0.812), while a clinical-radiomics nomogram achieved an AUC of 0.853 and radiogenomic analyses associated high-risk signatures with angiogenesis, EMT, inflammatory pathways, and resting mast-cell infiltration.
The evidence supports noninvasive identification of an aggressive HCC subtype and exploratory associations with molecular and immune features; it can only be inferred—not concluded—that this approach might eventually guide risk-adapted treatment selection or enrollment in studies targeting angiogenic, EMT-related, or immune pathways.
This narrative review summarizes multidisciplinary pediatric craniopharyngioma management, highlighting molecular subtypes, anatomy-guided hypothalamus-sparing surgery, modern radiotherapy, and emerging targeted and intracystic treatments aimed at preserving long-term function.
The review reports that risk-adapted surgery— including subtotal resection with modern radiotherapy in selected patients—may preserve hypothalamic and other functions while maintaining tumor control, and it identifies subtype-associated molecular alterations as potential therapeutic entry points; however, the supplied record does not provide primary comparative or trial evidence establishing the safety or efficacy of these strategies.
